Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Drug utilization studies

2,406 views

Published on

DUS- seminar

Published in: Health & Medicine
  • Be the first to comment

Drug utilization studies

  1. 1. DRUG UTILIZATION STUDIES DR.RENJU.S.RAVI MD
  2. 2. OVERVIEW  Introduction  Definition  Aims & Objectives  Types of drug use information  Targets  Tools used  DUE  Sources of data on DU  Future perspectives.
  3. 3. INTRODUCTION  Developed in mid 1960s in Northern Europe & UK.  Pioneering work by Arthur Engel in Sweden & Pieter Siderius in Holland.  Ultimate goal was to assess rational drug therapy.
  4. 4. DEFINITION “the marketing , distribution , prescription , and the use of drugs in a society with special emphasis on the resulting medical , social and economic consequences”.
  5. 5. AIMS & OBJECTIVES Description of drug use patterns Early signals of irrational drug use Interventions to improve drug use Quality control of drug use
  6. 6. Description of drug use patterns  Estimating the no: of patients exposed to drugs in a given time period.  Extent of drug use at a certain moment and/or certain area.  Extent of drug usage – proper/overuse/underuse  Drug use profile – assessing alternative drugs.  Comparing observed patterns of drug use to current guide lines.  Feed back to prescribers on DU data.  Relating the no: of case reports about adverse effects to the no: of pts exposed to assess the magnitude of the problem.
  7. 7. Early signals of IRRATIONAL DRUG USE  Helps to generate hypotheses for further drug investigations.  Comparing drug utilization patterns and costs b/w different regions or time periods.  Comparing observed patterns of drug use to current recommendations/guidelines.
  8. 8. Interventions to improve drug use  Monitoring and evaluating the improvement measures- information campaigns , regulatory policies.  Following the impact of regulatory changes / changes in insurance/reimbursement systems.  Assessing promotional activities of pharmaceutical industry, educational activities of society’s impact on pattern of drug use.
  9. 9. Quality control of drug use PLAN Analyse current situation to establish a plan for improvemen DO Implement plan on a small scale CHECK Check for the expected results ACT Revise or implement plan on large scale
  10. 10. Types of drug information  Drug based information  Problem or encounter-based information  Patient information  Prescriber information
  11. 11. TARGETS  Systems and structures surrounding drug use  Processes of drug use  Outcomes of drug use TYPES  Quantitative  Qualitative 1. Cross-sectional study 2. Longitudinal 3. Continuous longitudinal
  12. 12. TOOLS USED  WHO’s drug use indicators  Drug classification systems  Defined daily systems
  13. 13. Drug Utilization Evaluation  OBJECTIVES 1. Ensuring current drug therapy 2. Controlling drug cost 3. Preventing problem related to medication 4. Evaluating the effectiveness of drug therapy 5. Identification of areas of practice that require further education of practitioners
  14. 14. DUE Classification PROSPECTIVE CONCURRENT RETROSPECTIVE
  15. 15. Sources of data on drug utilization 1. Large data base 2. Data from drug regulatory agencies 3. Supplier/distribution data 4. Practice setting data a) Prescribing data b) Dispensing data c) Aggregate data d) OTC & Pharmacist-prescribed drugs e) Telephone & Internet prescribing 5. Community setting data.
  16. 16. Future Perspectives 1. Public health – diff b/w national & international patterns of drug utilization requires further study. 2. Pharmacovigilance – DU data can be used to perform screening pts with ↑ risk for drug induced illnesses. 3. Pharmacoeconomics – by adhering to current guidelines  reduce drug expenditure & improve limited resources.
  17. 17. 4. Eco pharmacovigilance – pharmaceuticals are environmental pollutants care to be taken to ↓ environmental impacts while delivering patient benefit. 5. Pharmacogenetics – assessing genetic mechanisms related to drug safety, comparing pts characteristics to the benefit and risk of drugs.
  18. 18. THANK YOU

×